Skip to content

    Solara Active Pharma Sciences Limited

    SOLARA
    Healthcare·25 Jul 2025
    Management Summary

    Solara Active Pharma Sciences reported a strong Q1 FY26, with significant QoQ growth in revenue, EBITDA, and PAT, driven by a focus on high-margin business and cost containment. The company made substantial progress in debt reduction, lowering its net debt to EBITDA ratio. While the core API business showed resilience, the CRAMS division is in an investment phase, with expectations of a tepid year before becoming a meaningful contributor in 2-3 years.

    Highlights

    5

    • Revenue grew 15% QoQ to ₹320 crores, indicating a strong start to FY26.

    • Gross margin remained healthy at 54%, with absolute gross margin at ₹173 crores (up 8% QoQ).

    • EBITDA of ₹57 crores reflects a 13% QoQ and 36% YoY growth, with an 18% margin.

    • PAT of ₹105 million is the highest in the last 12+ quarters, resulting in a positive EPS of ₹2.5.

    • Debt reduced by ₹143 crores (18% of opening debt), primarily from rights issue proceeds and operational cash flows.

    Concerns

    3

    • CRAMS business is expected to have a 'tepid year' in FY26 due to significant investments and repurposing of the Vizag plant.

    • Ibuprofen market continues to face intense competitive pressure from new entrants and pricing challenges.

    • The push of ₹200 crores debt to the newly formed CRAMS company (Synthix Global Pharma Solutions) implies a need for equity infusion.

    Key financials

    Single quarter

    07 metrics
    1. 01Revenue₹320 Cr+15%QoQ
    2. 02Gross Margin54%
    3. 03Absolute Gross Margin₹173 Cr+8%QoQ
    4. 04EBITDA₹57 Cr+36%YoY
    5. 05EBITDA Margin18%

    Capital allocation

    2
    high confidence
    CategoryHeadline
    Capex

    Capex disclosed

    Debt

    2.7x EBITDA

    Guidance & targets

    9
    CategoryTargetPriority
    Revenue
    Top line growth
    around 10%
    		High
    Profitability
    EBITDA growth
    around 15% to 20%
    		High
    Profitability
    EBITDA range
    INR 240-250 crores
    		Medium
    Debt
    Net debt to EBITDA
    sub INR450 crores level, which will reflect a net debt-to-EBITDA ratio of 1.5x
    		High
    Debt
    Net debt to EBITDA (post CRAMS debt push)
    less than 1
    		Medium
    CRAMS Business Growth
    CRAMS revenue growth
    from INR100 crores to maybe, let's say, 4, 5x
    		Medium
    Capex
    CRAMS capex and loss funding
    INR200 crores in the first phase
    		High
    Capex
    CRAMS business target size from capex
    INR400 crores, INR500 crores
    		Medium
    Margin
    Gross margin in Catalogue API segment
    53% to 55%
    		High

    What to watch in Q2 FY26

    5

    CRAMS business fund raising details

    next call
    CurrentImplied need for equity infusion
    TargetSpecifics on pref or rights issue

    Why it matters

    This will determine the capital structure and funding strategy for the newly formed CRAMS entity.

    Also, as you mentioned about the equity for the CRAMS business, the fund raising, will it be a pref or like a rights issue? ... It's very early days💬 for now. We will probably have more answers for you in the next call.

    Risks & concerns

    3
    RiskSeverity

    Intense competition and pricing pressure in Ibuprofen market

    New entrants, new chemistry, and pricing challenges persist, leading Solara to focus on derivatives and complex programs. — Management acknowledged

    high

    Tepid growth and significant investments for CRAMS business in near term

    FY26 is expected to be a tepid year for CRAMS due to necessary investments in repurposing the Vizag plant, with meaningful business expected in 2-3 years. — Management acknowledged

    medium

    Need for equity infusion for CRAMS company

    Pushing ₹200 crores of debt to the newly formed CRAMS company (Synthix Global Pharma Solutions) will likely necessitate an equity infusion to maintain a healthy balance sheet. — Analyst acknowledged

    medium

    Q&A highlights

    8

    “So the run rate, Vishal, for that business as we when we announced the CRAMS carve out, it's just about INR100 crores. So we are INR100 crores on an annualized basis. So currently, the run rate is within that range, quarterly run rate. ... So to be honest with you, we have to make some significant investments to build out the CRAMS division in terms of repurposing the Vizag plant, which is what we are in the process of getting our redesign done. So I think this year will also be quite a tepid year for that division.”

    Clarifies the current scale and near-term outlook for the CRAMS business, indicating a period of investment rather than immediate growth.

    asked by Vishal, Systematix Group

    2 min read5 chapters

    Detailed Narrative

    01

    Strong Q1 FY26 Performance and Strategic Reset

    Solara Active Pharma Sciences commenced FY26 with robust performance, achieving ₹320 crores in revenue, a 15% QoQ increase. The company's gross margin stood at a healthy 54%, contributing ₹173 crores in absolute gross margin, up 8% QoQ. EBITDA reached ₹57 crores, reflecting a 13% QoQ and 36% YoY growth, with an 18% margin. This strong start is attributed to a strategic reset focusing on margin expansion, debt reduction, and establishing good governance, with developed markets contributing a significant 77% of overall sales.

    02

    Debt Reduction and Balance Sheet Strengthening

    The company successfully reduced its debt by ₹143 crores in Q1 FY26, representing an 18% reduction from the beginning of the fiscal year. This reduction was primarily funded by ₹113 crores from the rights issue and ₹31 crores from operational cash flows. Consequently, the net debt to EBITDA ratio improved to 2.7x. Management targets further reduction to sub ₹450 crores by Q1 FY27, aiming for a 1.5x net debt to EBITDA ratio, and potentially less than 1x if ₹200 crores of debt is transferred to the CRAMS company.

    03

    CRAMS Business: Investment Phase and Long-term Vision

    The CRAMS division is currently in an investment phase, with FY26 anticipated to be a 'tepid year' due to significant capital expenditure for repurposing the Vizag plant. The company expects to invest at least ₹200 crores in capex and loss funding in the first phase, aiming to grow the CRAMS business from its current ₹100 crores annualized run rate to ₹400-500 crores over the next 3-4 years. Management confirmed that an equity infusion would likely be needed for the newly formed CRAMS entity, Synthix Global Pharma Solutions, to maintain a healthy balance sheet.

    04

    Ibuprofen Portfolio and Market Strategy

    Ibuprofen and its derivatives now constitute approximately 30% of Solara's business in Q1 FY26, a reduction from the previous 50% reliance. The company maintains that pricing for its ibuprofen products is stable due to a conscious strategy of serving only 'up-tier high-quality marquee customers' in developed markets. While the broader ibuprofen market faces intense competitive pressure from new entrants and pricing challenges, Solara is pivoting towards derivatives and more complex programs to mitigate these headwinds.

    05

    Operational Efficiency and Margin Sustainability

    Solara is actively pursuing cost improvement programs, operational efficiency, and network optimization to drive profitability. The company's capacity utilization stands at 60-65% across its facilities, with an asset turnover ratio close to 1.2. Management aims to sustain gross margins in the 53-55% range for its Catalogue API segment in FY26, emphasizing that the current 54% gross margin is healthy and reflects the quality of its business mix.

    This is an AI-generated summary of a publicly available earnings call transcript. It is for informational purposes only and does not constitute investment advice, a recommendation, or an endorsement. inve.money is not a SEBI-registered investment advisor. Please consult a qualified financial advisor before making any investment decisions.